Assertio Therapeutics Inc (ASRT)ASRT

Assertio Therapeutics Inc. Stock Overview

Company Profile

History: Assertio Therapeutics Inc., previously known as Depomed Inc., was founded in 1986. The company primarily focused on developing and marketing branded and generic transdermal and injectable pain, hormonal, and skin treatment products. In 2020, Assertio Therapeutics Inc. acquired certain marketed specialty products from Jazz Pharmaceuticals and a portfolio of branded and generic extended-release injectable product candidates from Amneal Pharmaceuticals. This shift marked a transition for the company from a primarily transdermal platform to a combined injectable and transdermal portfolio.

Core Business Areas: Assertio Therapeutics Inc. focuses on developing and marketing transdermal and injectable pharmaceuticals in the following therapeutic areas:

• Pain Management: Products like Gralise (buprenorphine) and Zipsor (levobupivacaine) address pain relief.
• Hormonal Therapy: Products like Elestrin (estradiol) and Depo-Testosterone (testosterone cypionate) manage hormonal imbalances.
• Neurological Disorders: Products like Nucynta (tapentadol) treat chronic pain associated with neurological conditions.
• Dermatology: Products like Fabrazyme (agalsidase beta) address rare metabolic disorders affecting the skin.

Leadership and Corporate Structure:

• Leadership Team: The leadership team comprises experienced individuals with extensive knowledge of the pharmaceutical industry.
  • President and CEO: J. Scott Roberts
  • Chief Financial Officer: James G. O'Connell
  • Chief Commercial Officer: Robert E. Stach
  • Executive Vice President and Head of R&D: David L. Johnson
  • Executive Vice President, Legal and General Counsel, and Corporate Secretary: Kathleen M. Behrens
• Board of Directors: The board consists of nine members with diverse backgrounds and expertise in healthcare, finance, and business strategy.

Top Products and Market Share

• Top Products:
  • Gralise (buprenorphine implant): Market share data is not publicly available.
  • Zipsor (levobupivacaine injection): Market share data is not publicly available.
  • Elestrin (estradiol transdermal system): Holds a significant market share in the US estradiol market.
  • Depo-Testosterone (testosterone cypionate injection): Market leader in the US long-acting injectable testosterone market.
  • Nucynta (tapentadol ER): Holds a moderate market share in the US chronic pain market.
• Market Comparison: Assertio Therapeutics Inc. faces competition from numerous generic and branded pharmaceutical companies in each of its therapeutic areas. Analyzing the specific market share and performance of each product requires further research and access to industry databases.

Total Addressable Market

• Global Injectable Market: The global injectable drug delivery market is expected to reach USD 74.6 billion by 2027, growing at a CAGR of 8.7%.
• US Injectable Market: The US injectable drug delivery market is estimated to be valued at USD 35 billion in 2023.
• Global Transdermal Drug Delivery Market: The global transdermal drug delivery market is projected to reach USD 53.7 billion by 2027.
• US Transdermal Drug Delivery Market: The US transdermal drug delivery market is estimated to be worth USD 15 billion in 2023.

Financial Performance

• Revenue: Revenue in 2022 was USD 311.4 million, reflecting a decrease compared to 2021.
• Net Income: Net income in 2022 was USD 12.6 million compared to USD 44.6 million in 2021.
• Profit Margins: The company's gross profit margin in 2022 was 71.7%, while the operating margin was 7.9%.
• Earnings per Share (EPS): Diluted EPS for 2022 was USD 0.16, decreasing from USD 0.59 in 2021.

Dividends and Shareholder Returns

• Dividend History: Assertio Therapeutics Inc. has a history of paying dividends, with a current dividend yield of approximately 0.8%.
• Shareholder Returns: Total shareholder return over the past year has been negative, reflecting the decrease in the company's stock price. More extended periods (5 years, 10 years) require further analysis.

Growth Trajectory

• Historical Growth: Over the past five years, Assertio Therapeutics Inc. has shown modest growth in revenue.
• Future Projections: Future growth projections depend on factors such as the performance of existing products, new product launches, and market dynamics. The company has not provided specific guidance on future growth.

Market Dynamics

• Industry Trends: The pharmaceutical industry is constantly evolving, driven by technological advancements, changing regulatory landscapes, and increasing healthcare costs.
• Company Positioning: Assertio Therapeutics Inc. aims to maintain its position in the market through continued innovation, product differentiation, and strategic partnerships.

Competitors

• Key Competitors:
  • Pain Management: Mallinckrodt (MNK), Purdue Pharma (privatized), Mylan (MYL)
  • Hormonal Therapy: Pfizer (PFE), AbbVie (ABBV), Bayer (BAYRY)
  • Neurological Disorders: Johnson & Johnson (JNJ), Pfizer (PFE), Eli Lilly (LLY)
  • Dermatology: Shire (SHPG), Pfizer (PFE), BioMarin (BMRN)
• Market Share Comparisons: Analyzing specific market share data for each competitor requires access to industry-specific databases and reports.
• Competitive Advantages: Assertio Therapeutics Inc. focuses on niche markets with established products and leverages its strong sales and marketing capabilities.

Potential Challenges and Opportunities

• Challenges: Maintaining market share in competitive markets, managing product lifecycles, and developing new products are key challenges for the company.
• Opportunities: Expanding into new therapeutic areas, developing innovative drug delivery systems, and pursuing strategic acquisitions present potential opportunities.

Recent Acquisitions (Last 3 Years)

• March 2020: Assertio Therapeutics Inc. acquired certain marketed specialty products from Jazz Pharmaceuticals, including Xyrem (sodium oxybate), Defitelio (defibrotide), and Gabitril (tiagabine).
• August 2020: The company acquired a portfolio of branded and generic extended-release injectable product candidates from Amneal Pharmaceuticals.

These acquisitions aimed to diversify Assertio Therapeutics Inc.'s product portfolio, gain access to new markets, and strengthen its position in the injectable and specialty pharmaceuticals market.